Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.:

Related Articles

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.

J Nucl Med. 2020 Jan 31;:

Authors: Kamel Hasan O, Ravi Kumar AS, Kong G, Oleinikov K, Ben-Haim S, Grozinsky-Glasberg S, Hicks RJ

Abstract

Objectives: Esthesioneuroblastoma (ENB) is rare with limited therapeutic options when unresectable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT). We report outcomes of PRRT in ENB from two referral centers. Methods: Using PRRT databases at two European Neuroendocrine Tumour Society Centers of Excellence, case finding was undertaken between 2004-2018 for patients who had PRRT with recurrent/metastatic ENB deemed unsuitable for further conventional therapies. Evaluations of response using a composite reference standard and for survival were performed. Results: Of seven patients, four had partial response, two had disease stabilization and one had early progression. Possible side effects include worsening CSF-leaks. Median progression-free survival was 17 months (range, 0-30), and median overall survival was 32 months (range, 4-53). Conclusion: PRRT shows promising efficacy and moderate survival duration in unresectable locally advanced or metastatic ENB warranting larger cohort studies incorporating measures of quality of life.

PMID: 32005769 [PubMed - as supplied by publisher]